title: E1 pyruvate dehydrogenase deficiency in a child with motor neuropathy.
abstract: We report the case of a boy who developed a motor neuropathy during infectious episodes at 18 mo and 3 y of age. When he was 7 y old, he suffered persistent weakness and areflexia; his resting lactate and pyruvate values were 3.65 mM and 398 microM, respectively (controls: 1.1 +/- 0.3 mM and 90 +/- 22 microM), and an exercise test demonstrated a lactic acidosis (13.6 mM; controls: 6.4 +/- 1.3 mM) with a high pyruvate level (537 microM; controls: 176 +/- 15 microM) and a low lactate/pyruvate ratio (24.2; controls: 35 +/- 2). The results of polarographic studies on muscle mitochondria suggested a defect in pyruvate oxidation (pyruvate 17 ng atom O/min/mg protein; controls: 115 +/- 42), whereas glutamate, palmitoylcarnitine, and succinate were good respiratory substrates. The activity of total pyruvate dehydrogenase complex (PDHC) in muscle mitochondria and in fresh mononuclear cells was markedly decreased (9.7 and 0.054 nmol 14CO2/min/mg protein, respectively; controls: 123 +/- 4.5 and 0.733 +/- 0.03, respectively). Immunochemical analysis in muscle mitochondria demonstrated an absence of the alpha and beta E1 PDHC subunits. After 2 y of treatment with 500 mg/d thiamine, the patient was clinically improved. A genetic study of the main regions of mutations (exon 10 and 11) in the X chromosome encoding for the E1 alpha subunit of PDHC did not show any mutation. These data indicate that, although genetically different, this case enters in a very rare category of patients with PDHC deficiency without cerebral dysfunction and improved by thiamine + L-carnitine therapy.
authors.affiliation: INSERM U 75, Faculté Necker, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Bonne
authors.forename: C
authors.initials: C
authors.lastname: Benelli
authors.forename: L
authors.initials: L
authors.lastname: De Meirleir
authors.forename: W
authors.initials: W
authors.lastname: Lissens
authors.forename: M
authors.initials: M
authors.lastname: Chaussain
authors.forename: M
authors.initials: M
authors.lastname: Diry
authors.forename: J P
authors.initials: JP
authors.lastname: Clot
authors.forename: G
authors.initials: G
authors.lastname: Ponsot
authors.forename: V
authors.initials: V
authors.lastname: Geoffroy
authors.forename: J P
authors.initials: JP
authors.lastname: Leroux
mesh_terms: D001483:Base Sequence; D002331:Carnitine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D004247:DNA / Q000235:genetics; D004252:DNA Mutational Analysis; D004359:Drug Therapy, Combination; D006801:Humans; D008214:Lymphocytes / Q000201:enzymology; D008297:Male; D008931:Mitochondria, Muscle / Q000201:enzymology; D008969:Molecular Sequence Data; D016472:Motor Neuron Disease / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology; D011768:Pyruvate Dehydrogenase Complex / Q000235:genetics / Q000276:immunology; D015325:Pyruvate Dehydrogenase Complex Deficiency Disease / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D013831:Thiamine / Q000008:administration & dosage / Q000627:therapeutic use; D014960:X Chromosome
chemical_list: D011768:Pyruvate Dehydrogenase Complex; D004247:DNA; D002331:Carnitine; D013831:Thiamine